241 related articles for article (PubMed ID: 25373851)
1. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation.
Hudzik B; Danikiewicz A; Szkodzinski J; Polonski L; Zubelewicz-Szkodzinska B
Eur Cytokine Netw; 2014; 25(3):41-5. PubMed ID: 25373851
[TBL] [Abstract][Full Text] [Related]
2. Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare-metal stent compared to drug-eluting stent implantation.
Hudzik B; Szkodzinski J; Pietka-Rzycka A; Danikiewicz A; Wojnar R; Lekston A; Polonski L; Zubelewicz-Szkodzinska B
J Interferon Cytokine Res; 2013 May; 33(5):280-4. PubMed ID: 23414296
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
Haibo L; Xiaofang G; Chunming W; Jie Y; Guozhong C; Limei Z; Yong C; Yu F; Yingchun B; Wangjun Y; Junbo G
Mediators Inflamm; 2014; 2014():963096. PubMed ID: 25538378
[TBL] [Abstract][Full Text] [Related]
4. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.
Soeki T; Niki T; Kusunose K; Bando S; Hirata Y; Tomita N; Yamaguchi K; Koshiba K; Yagi S; Taketani Y; Iwase T; Yamada H; Wakatsuki T; Akaike M; Sata M
J Cardiol; 2011 Sep; 58(2):151-7. PubMed ID: 21676590
[TBL] [Abstract][Full Text] [Related]
5. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein.
Zhou Y; Ni Z; Zhang J; Zhang W; Wu Q; Shen G; Wang Y; Qian J
Vasc Med; 2013 Apr; 18(2):85-91. PubMed ID: 23609129
[TBL] [Abstract][Full Text] [Related]
6. Pentraxin 3 and C-reactive protein in severe meningococcal disease.
Sprong T; Peri G; Neeleman C; Mantovani A; Signorini S; van der Meer JW; van Deuren M
Shock; 2009 Jan; 31(1):28-32. PubMed ID: 18650775
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease.
Hollan I; Bottazzi B; Cuccovillo I; Førre ØT; Mikkelsen K; Saatvedt K; Almdahl SM; Mantovani A; Meroni PL;
Arthritis Care Res (Hoboken); 2010 Mar; 62(3):378-85. PubMed ID: 20391484
[TBL] [Abstract][Full Text] [Related]
8. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
[TBL] [Abstract][Full Text] [Related]
9. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein.
Yasunaga T; Ikeda S; Koga S; Nakata T; Yoshida T; Masuda N; Kohno S; Maemura K
Int Heart J; 2014; 55(2):160-4. PubMed ID: 24632958
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.
Inoue K; Sugiyama A; Reid PC; Ito Y; Miyauchi K; Mukai S; Sagara M; Miyamoto K; Satoh H; Kohno I; Kurata T; Ota H; Mantovani A; Hamakubo T; Daida H; Kodama T
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):161-7. PubMed ID: 17095712
[TBL] [Abstract][Full Text] [Related]
11. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain.
Brügger-Andersen T; Pönitz V; Kontny F; Staines H; Grundt H; Sagara M; Nilsen DW
Thromb Haemost; 2009 Sep; 102(3):555-63. PubMed ID: 19718477
[TBL] [Abstract][Full Text] [Related]
12. PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS.
Kizilgul M; Beysel S; Ozcelik O; Kan S; Apaydin M; Caliskan M; Ucan B; Sencar E; Ozdemir S; Cakal E
Endocr Pract; 2017 Jun; 23(6):662-668. PubMed ID: 28332877
[TBL] [Abstract][Full Text] [Related]
13. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease.
Nishi K; Imamura T; Kitamura K; Ogawa T; Fujimoto S; Kakitsubata Y; Ishikawa T; Asada Y; Kodama T
Ren Fail; 2011; 33(4):398-404. PubMed ID: 21529268
[TBL] [Abstract][Full Text] [Related]
14. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases.
Norata GD; Garlanda C; Catapano AL
Trends Cardiovasc Med; 2010 Feb; 20(2):35-40. PubMed ID: 20656213
[TBL] [Abstract][Full Text] [Related]
15. Pentraxin-3 expression in acute renal allograft rejection.
Imai N; Nishi S; Yoshita K; Ito Y; Osawa Y; Takahashi K; Nakagawa Y; Saito K; Takahashi K; Narita I
Clin Transplant; 2012 Jul; 26 Suppl 24():25-31. PubMed ID: 22747472
[TBL] [Abstract][Full Text] [Related]
16. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.
Kasperska-Zajac A; Grzanka A; Misiolek M; Mazur B; Machura E
Cytokine; 2015 Dec; 76(2):566-568. PubMed ID: 25982553
[TBL] [Abstract][Full Text] [Related]
17. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial.
Miyazaki T; Chiuve S; Sacks FM; Ridker PM; Libby P; Aikawa M
PLoS One; 2014; 9(4):e94073. PubMed ID: 24705587
[TBL] [Abstract][Full Text] [Related]
18. Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome?
Sari U; Kaygusuz I; Kafali H
Gynecol Obstet Invest; 2014; 78(3):173-8. PubMed ID: 25011417
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Plasma Pentraxin 3 Concentration and Platelet Indices in Patients With Stable Coronary Artery Disease.
Korzonek-Szlacheta I; Danikiewicz A; Szkodziński J; Nowak J; Lekston A; Gąsior M; Zubelewicz-Szkodzińska B; Hudzik B
Angiology; 2018 Mar; 69(3):264-269. PubMed ID: 28946774
[TBL] [Abstract][Full Text] [Related]
20. Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques.
Matsuura Y; Hatakeyama K; Imamura T; Tsuruda T; Shibata Y; Kodama T; Kitamura K; Asada Y
J Atheroscler Thromb; 2012; 19(9):837-45. PubMed ID: 22785134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
